Effects of Coenzyme Q10 on Arterial Stiffness, Metabolic Parameters, and Fatigue in Obese Subjects: A Double-Blind Randomized Controlled Study

다국어 초록 (Multilingual Abstract)

This study investigated the effects of coenzyme Q10 supplementation on metabolic parameters, inflammatory markers, arterial stiffness, and fatigue in obese subjects. We performed a randomized, double-blind, placebo-controlled, single-center study on 51 obese subjects with a body mass index (BMI) of ≥25 kg/m2. Subjects were randomized into either a coenzyme Q10 (200 mg/day) group (n = 26, BMI = 27.9 ± 2.3 kg/m2, age = 42.7 ± 11.3 years) or a placebo group (n = 25, BMI = 26.8 ± 2.8 kg/m2, age = 41.3 ± 11.2 years) for a 12-week study. We collected anthropometric measurements, blood for laboratory testing, brachial–ankle pulse wave velocity (baPWV) as an indicator of arterial stiffness, and responses to a fatigue severity scale (FSS) questionnaire at the initial (0 week) and final (12 weeks) visits. A total of 36 subjects successfully completed the study protocol. Serum coenzyme Q10 levels increased significantly from 0.65 ± 0.27 μg/mL to 1.20 ± 0.38 μg/mL in the coenzyme Q10 group (P < .001). Oral administration of coenzyme Q10 did not significantly affect lipid profiles, oxidative and inflammatory markers [including lipoprotein (a), oxidized low-density lipoprotein level, C-reactive protein, and white blood cell count], or baPWV. The mean FSS score decreased significantly from 40.1 to 33.1 in the coenzyme Q10 group (P = .017), but no significant change was seen in the placebo group (P = .464). However, the extents of the change in mean FSS score between the placebo and coenzyme Q10 groups were not significantly different (P = .287). In conclusion, we found no evidence that coenzyme Q10 affects fatigue index, arterial stiffness, metabolic parameters, or inflammatory markers.

참고문헌 (Reference)

1 Rogge MM, "The role of impaired mitochondrial lipid oxidation in obesity" 10 : 356-373, 2009

2 Lenaz G, "The role of Coenzyme Q in mitochondrial electron transport" 7 (7): S8-S33, 2007

3 Navas P, "The importance of plasma membrane coenzyme Q in aging and stress responses" 7 (7): S34-S40, 2007

4 Krupp I, "The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erytheromatosus" d46 : 1121-1123, 1989

5 Dhanasekaran M, "The emerging role of coenzyme Q-10 in aging, neurodegeneration, cardiovascular disease, cancer and diabetes mellitus" 2 : 447-459, 2005

6 Rosenfeldt F, "Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure" 18 : 91-100, 2003

7 Estornell E, "Saturation kinetics of coenzyme Q in NADH and succinate oxidation in beef heart mitochondria" 311 : 107-109, 1992

8 Lean ME, "Pathophysiology of obesity" 331-336, 2000

9 Werbach MR, "Nutritional strategies for treating chronic fatigue syndrome" 5 : 93-108, 2000

10 Højlund K, "Mitochondrial dysfunction in type 2 diabetes and obesity" 37 : 713-731, 2008

11 Puddu P, "Mitochondrial dysfunction as an initiating event in atherogenesis: a plausible hypothesis" 103 : 137-141, 2005

12 Qatanani M, "Mechanisms of obesity-associated insulin resistance: many choices on the menu" 21 : 1443-1455, 2007

13 Thomas SR, "Inhibition of LDL oxidation by ubiquinol-10. A protective mechanism for coenzyme Q in atherogenesis" 18 (18): S85-S103, 1997

14 Hulens M, "Exercise capacity in lean versus obese women" 11 : 305-309, 2001

15 Kelley DE, "Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes" 51 : 2944-2950, 2002

16 Ritov VB, "Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes" 54 : 8-14, 2005

17 Nisoli E, "Defective mitochondrial biogenesis: a hallmark of the high cardiovascular risk in the metabolic syndrome" 100 : 795-806, 2007

18 Rosenfeldt FL, "Coenzyme Q10 in the treatment of hypertension: a metaanalysis of the clinical trials" 21 : 297-306, 2007

19 Shults CW, "Coenzyme Q10 in neurodegenerative diseases" 10 : 1917-1921, 2003

20 Watts GF, "Coenzyme Q10 improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus" 45 : 420-426, 2002

21 Chew GT, "Coenzyme Q10 and diabetic endotheliopathy:oxidative stress and the recoupling hypothesis" 97 : 537-548, 2004

22 Lenaz G, "Coenzyme Q deficiency in mitochondria: kinetic saturation versus physical saturation" 18 (18): S25-S31, 1997

23 Hodgson JM, "Can coenzyme Q10 improve vascular function and blood pressure? Potential for effective therapeutic reduction in vascular oxidative stress" 18 : 129-136, 2003

24 Crane FL, "Biochemical functions of coenzyme Q10" 20 : 591-598, 2001

25 Holvoet P, "Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome" 299 : 2287-2293, 2008

26 Mizuno K, "Antifatigue effects of coenzyme Q10 during physical fatigue" 24 : 293-299, 2008

27 Hopps E, "A novel component of the metabolic syndrome: the oxidative stress" 20 : 72-77, 2009